EUROPEAN UROLOGY 65 (2014) 480–489
available at www.sciencedirect.com
journal homepage: www.europeanurology.com
Guidelines
European Association of Urology Guidelines on Priapism
Andrea Salonia a, Ian Eardley b, François Giuliano c, Dimitrios Hatzichristou d,
Ignacio Moncada e, Yoram Vardi f, Eric Wespes g, Konstantinos Hatzimouratidis h,*
a
Department of Urology, University Vita-Salute San Raffaele, Milan, Italy; b Department of Urology, St. James University Hospital, Leeds, UK; c Versailles Saint
Quentin en Yvelines University, Garches, France, Neurology-Urology-Andrology, Department of Physical Medicine and Rehabilitation, Raymond Poincaré
Hospital, Garches, France;
d
Aristotle University of Thessaloniki, Centre for Sexual and Reproductive Health and 2nd Department of Urology, Thessaloniki,
e
Greece; Department of Urology, Hospital Sanitas La Zarzuela, Madrid, Spain; f Neuro-Urology Unit, Rambam Healthcare Campus, and the Rappaport Faculty
of Medicine, Technion-IIT, Haifa, Israel; g Department of Urology, CHU de Charleroi, Hôpital Erasme, Brussels, Belgium; h 2nd Department of Urology, Aristotle
University of Thessaloniki, Thessaloniki, Greece
Article info
Abstract
Article history:
Accepted November 5, 2013
Published online ahead of
print on November 16, 2013
Context: Priapism is defined as a penile erection that persists beyond or is unrelated to
sexual interest or stimulation. It can be classified into ischaemic (low flow), arterial (high
flow), or stuttering (recurrent or intermittent).
Objective: To provide guidelines on the diagnosis and treatment of priapism.
Evidence acquisition: Systematic literature search on the epidemiology, diagnosis, and
treatment of priapism. Articles with highest evidence available were selected to form the
basis of these recommendations.
Evidence synthesis: Ischaemic priapism is usually idiopathic and the most common
form. Arterial priapism usually occurs after blunt perineal trauma. History is the
mainstay of diagnosis and helps determine the pathogenesis. Laboratory testing is used
to support clinical findings. Ischaemic priapism is an emergency condition. Intervention
should start within 4–6 h, including decompression of the corpora cavernosa by aspiration and intracavernous injection of sympathomimetic drugs (e.g. phenylephrine).
Surgical treatment is recommended for failed conservative management, although
the best procedure is unclear. Immediate implantation of a prosthesis should be
considered for long-lasting priapism. Arterial priapism is not an emergency. Selective
embolization is the suggested treatment modality and has high success rates. Stuttering
priapism is poorly understood and the main therapeutic goal is the prevention of future
episodes. This may be achieved pharmacologically, but data on efficacy are limited.
Conclusions: These guidelines summarise current information on priapism. The extended version are available on the European Association of Urology Website (www.
uroweb.org/guidelines/).
Patient summary: Priapism is a persistent, often painful, penile erection lasting more
than 4 h unrelated to sexual stimulation. It is more common in patients with sickle cell
disease. This article represents the shortened EAU priapism guidelines, based on a
systematic literature review. Cases of priapism are classified into ischaemic (low flow),
arterial (high flow), or stuttering (recurrent). Treatment for ischaemic priapism must be
prompt in order to avoid the risk of permanent erectile dysfunction. This is not the case
for arterial priapism.
# 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Keywords:
Priapism
EAU guidelines
Ischaemic
Arterial
Stuttering
Diagnosis
Treatment
Medical treatment
* Corresponding author. Aristotle University of Thessaloniki. Kimiseos Theotokou 26B, 57010 Pefka,
Thessaloniki, Greece. Tel. +30 23 10 99 15 43; Fax: +30 23 10 67 60 92.
E-mail address: promahon@otenet.gr (K. Hatzimouratidis).
0302-2838/$ – see back matter # 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.eururo.2013.11.008
EUROPEAN UROLOGY 65 (2014) 480–489
1.
Introduction
Priapism is a pathologic condition representing a true
disorder of penile erection that persists beyond or is
unrelated to sexual interest or stimulation [1]. Overall,
erections lasting up to 4 h are by consensus defined as
prolonged (level of evidence [LE]: 4). Priapism may occur at
all ages. Current data show that the incidence of priapism in
the general population is low (0.5–0.9 cases per 100 000
person-years) [2,3]. In patients with sickle cell disease,
which is an inherited disease that causes chronic haemolytic anaemia, the prevalence of priapism is up to 3.6% in
patients <18 yr of age [4] increasing up to 42% in patients
18 yr of age [5–7].
2.
Methodology
A systematic literature search of the Medline database was
performed. The controlled vocabulary of the Medical
Subject Headings database was searched using the term
priapism. This search yielded 1199 articles (125 review
articles, 404 original articles, and 670 case reports). The
expert panel also identified critical problems and knowledge gaps, enabling priorities to be established for future
clinical research. These European Association of Urology
(EAU) guidelines on priapism were presented for the first
time by the EAU Male Sexual Dysfunction Guidelines Panel.
3.
Classification
3.1.
Ischaemic (low-flow or veno-occlusive) priapism
Ischaemic priapism is a persistent erection marked by
rigidity of the corpora cavernosa and by little or no cavernous
arterial inflow [8]. The patient typically complains of penile
pain, and the examination reveals a rigid erection. Resolution
of ischaemic priapism is characterised by the penis returning
to a flaccid nonpainful state. However, in many cases,
persistent penile oedema, ecchymosis, and partial erections
can occur that may mimic unresolved priapism.
When left untreated, resolution may take days, and
erectile dysfunction invariably results.
3.2.
Arterial (high-flow or nonischaemic) priapism
Arterial priapism is a persistent erection caused by
unregulated cavernous arterial inflow [8]. The patient
typically reports an erection that is not fully rigid and
not associated with pain. Fully rigid erections under sexual
stimulation may occur before returning to the previous
state of penile tumescence. In this case, it is not associated
with erectile dysfunction.
3.3.
Stuttering (recurrent or intermittent) priapism
Stuttering priapism, also termed intermittent or recurrent
priapism, is a distinct condition characterised by repetitive,
painful episodes of prolonged erections. Erections are selflimited with intervening periods of detumescence [9]. The
481
duration of the erectile episodes in stuttering priapism is
generally shorter than in the low-flow ischaemic type [1].
The frequency and/or duration of these distressing priapic
episodes may increase, and a single episode can sometimes
develop into a major period of ischaemic priapic episodes.
4.
Epidemiology and pathophysiology
4.1.
Ischaemic (low-flow or veno-occlusive) priapism
Ischaemic priapism is the most common form of priapism,
accounting for >95% of all priapism episodes [8,10]. In
ischaemic priapism, there are time-dependent modifications in the corporal metabolic environment, progressively
leading to hypoxia, hypercapnia, and acidosis.
Ischaemic priapism beyond 4 h is considered a compartment syndrome, characterised by pressure within the
closed space of the corpora cavernosa that severely
compromises circulation in the cavernous tissues. A
compartment syndrome requires emergency medical intervention to minimise potential irreversible consequences
such as corporal fibrosis and permanent erectile dysfunction [11,12]. The duration of priapism represents the most
significant predictor of the maintenance of premorbid
erectile function; in this context, interventions beyond 48–
72 h since onset may eventually help relieve erection and
pain, but they have little benefit in preserving erectile
functioning. Histologically, by 12 h, corporal specimens
show interstitial oedema, progressing to destruction of
sinusoidal endothelium, exposure of the basement membrane, and thrombocyte adherence at 24 h. At 48 h, thrombi
can be found in the sinusoidal spaces, and smooth muscle
necrosis with fibroblast-like cell transformation is evident
[12].
In terms of pathophysiology (Table 1), ischaemic
priapism has been identified as idiopathic in most cases
[8,13]. Moreover, ischaemic priapism has been associated
with sickle cell anaemia, haematologic dyscrasias, neoplastic syndromes, and the use of several different medications.
Ischaemic priapism occurs relatively often (0.4–35%) after
intracavernous injections of papaverine, phentolamine,
and/or prostaglandin E1 [8,14–16] (Table 1). However,
most of these cases were treated with papaverine-based
combinations; the prevalence of priapism is <1% in the case
of prostaglandin E1 [15]. Since their introduction on the
market, a few cases of priapism have been described in
men who have taken phosphodiesterase type 5 inhibitors
(PDE5-Is) [8]. Most of these men had histories of increased
risk for priapism including sickle cell disease, spinal cord
injury, combined administration of PDE5-I and intracavernosal injection of vasoactive agents, a history of penile
trauma, abuse of narcotics or psychotropic medication, or
taking PDE5-I for recreational purposes without a medical
reason [8].
Sickle cell disease is the most common aetiology of
ischaemic priapism in childhood, accounting for 63% of the
cases. It is the primary aetiology in 23% of adult cases of
priapism, with a lifetime probability of developing ischaemic priapism of 29–42% in men with sickle cell disease
482
EUROPEAN UROLOGY 65 (2014) 480–489
Table 1 – Potential causative factors for ischaemic priapism
Idiopathic
Haematologic dyscrasias (sickle cell disease, thalassemia, leukaemia;
multiple myeloma, haemoglobin Olmsted variant, fat emboli during
hyperalimentation, haemodialysis, glucose-6-phosphate dehydrogenase
deficiency, factor V Leiden mutation)
Infections (toxin mediated) (ie, scorpion sting, spider bite, rabies,
malaria)
Metabolic disorders (ie, amyloidosis, Fabry disease, gout)
Neurogenic disorders (ie, syphilis, spinal cord injury, cauda equina
syndrome, autonomic neuropathy, lumbar disc herniation, spinal
stenosis, cerebrovascular accident, brain tumour, spinal anaesthesia)
Neoplasms (metastatic or regional infiltration) (ie, prostate, urethra,
testis, bladder, rectal, lung, kidney)
Medications
* Vasoactive erectile agents (ie, papaverine, phentolamine,
prostaglandin E1/alprostadil, combination of intracavernous
therapies)
* a-Adrenergic receptor antagonists (ie, prazosin, terazosin,
doxazosin, tamsulosin)
* Antianxiety agents (hydroxyzine)
* Anticoagulants (heparin, warfarin)
* Antidepressants and antipsychotics (ie, trazodone, bupropion,
fluoxetine, sertraline, lithium, clozapine, risperidone, olanzapine,
chlorpromazine, thioridazine, phenothiazines)
* Antihypertensives (ie, hydralazine, guanethidine, propranolol)
* Hormones (ie, gonadotropin-releasing hormone, testosterone)
* Recreational drugs (ie, alcohol, marijuana, cocaine [intranasal and
topical], crack, cocaine)
[8,17,18] (LE: 4). Mechanisms of sickle cell disease–
associated priapism in the human penis may involve
dysfunctional nitric oxide synthase and r-associated
protein kinase signalling, and increased oxidative stress
associated with nicotinamide adenine dinucleotide phosphate oxidase-mediated signalling [19].
Priapism resulting from metastatic or regional infiltration is not widely studied or reported. The cases in the
literature seem to indicate this is an infiltrative and not a
haemodynamic process like ischaemic or high-flow priapism [20]. As such, the recommendations for pharmacologic
treatment are not likely to be effective. Certainly, all of these
men should be imaged with magnetic resonance imaging
and offered supportive care for their primary cancer.
4.2.
Arterial (high-flow or nonischaemic) priapism
Epidemiologic data on arterial priapism are almost exclusively derived from small case series [8,21,22]. The usual
cause of high-flow priapism is blunt perineal trauma [23].
The injury results in a laceration in the cavernosal artery
leading to a high-flow fistula between the artery and the
lacunar spaces of the sinusoidal tissue [24]. This unregulated flow results in a persistent erection, probably via a
mechanism that involves stimulation of endothelial nitric
oxide synthase by the turbulent blood flow [25]. Partial
erections are enhanced after sexual stimulation as the
trabecular smooth muscle fully relaxes, activating the
corporal veno-occlusive mechanism [26]. There is often a
delay between the injury and the development of the
priapism that may be up to 2–3 wk. This reflects either
spasm or ischaemic necrosis of the injured artery with the
fistula only developing as the spasm resolves or when the
ischaemic segment blows out.
Occasional cases are associated with metastatic malignancy to the penis [27], with acute spinal cord injury [28],
and following intracavernosal injections or aspiration
[29,30].
4.3.
Stuttering (recurrent or intermittent) priapism
Epidemiologic studies of stuttering priapism are lacking.
Our current understanding of this stressful entity has been
derived from observations in men with sickle cell disease in
which the incidence of priapism is high [7,31]. Specifically,
the incidence of recurrent episodes of priapism in men with
sickle cell disease is between 42% and 64% [32,33]. In a
multicentre study that involved 98 boys, adolescents, and
young men with sickle cell disease, ranging in age from 5 to
20 yr, the incidence of priapism was 35%, of whom 72% had a
history of stuttering priapism [7].
The aetiology of stuttering priapism is similar to that of
ischaemic priapism. Sickle cell disease is the most common
cause of stuttering priapism. The cause can also be
idiopathic and may rarely be due to a neurologic disorder.
Moreover, men who have experienced an acute ischaemic
priapic event, especially one that has been long lasting
(>4 h) may be at risk for developing stuttering priapism
[34]. The underlining mechanism is similar to that of other
types of ischaemic priapism: A deficiency of endothelial
nitric oxide in the penis causes downregulation of its
specific downstream effectors, a cyclic guanosine monophosphate (cGMP)-dependent protein kinase including
phosphodiesterase type 5 (PDE5) dysregulation [35,36].
Under this condition, the control system of corporal smooth
muscle tone is functioning at a low point. Hence the
response to any sexual or nonsexual stimulus, such as that
which can occur during rapid eye movement sleep, will
induce a prolonged erectile episode. Table 2 summarises the
conclusions on the epidemiology and pathophysiology of
priapism.
5.
Diagnostic evaluation of priapism
5.1.
History
A comprehensive history is the mainstay in priapism
diagnosis [8,37]. Table 3 lists the key points in the medical
history. The history can help determine the underlying type
of priapism (Table 4). Ischaemic priapism is associated with
progressive penile pain, and the erection is rigid. Although
most cases of ischaemic priapism are idiopathic, the patient
history may reveal one of the causes listed in Table 1.
5.2.
Physical examination
Physical examination of the genitalia, the perineum, and the
abdomen must be included in the diagnostic evaluation of
priapism [8,37]. In ischaemic priapism, the corpora are fully
rigid and tender, but the glans penis is soft. In arterial
priapism, the corpora are tumescent but not fully rigid
483
EUROPEAN UROLOGY 65 (2014) 480–489
Table 5 – Typical blood gas values*
Table 2 – Epidemiology and pathophysiology of priapism
Ischaemic priapism is the most common form of priapism,
accounting for >95% of all priapism episodes.
Ischaemic priapism is identified as idiopathic in the vast majority
of patients; sickle cell anaemia is the most common cause in
childhood.
Ischaemic priapism occurs relatively often (up to 35%) after
intracavernous injections of papaverine-based combinations,
although it is rare (<1%) after prostaglandin E1 monotherapy.
Priapism is rare in men who have taken phosphodiesterase type 5
inhibitors, with only sporadic cases reported.
Arterial priapism usually occurs after blunt perineal trauma.
The aetiology of stuttering priapism is the same as that for the
ischaemic type. Although sickle cell disease is the most common
aetiology of this entity, the cause can also be idiopathic and may
rarely be due to a neurologic disorder.
LE
Source
1b
Normal arterial blood
(room air)
Normal mixed venous
blood (room air)
Ischaemic priapism
(first corporal aspirate)
1b
2a
*
2
3
Table 3 – Key points in taking the history of priapism
Duration of erection
Presence and degree of pain
Previous episodes of priapism and method of treatment
Current erectile function, especially the use of any erectogenic therapies
prescription or nutritional supplements
Medications and recreational drugs
Sickle cell disease, haemoglobinopathies, hypercoagulable states
Trauma to the pelvis, perineum, or penis
Adapted from Broderick et al. [8].
(Table 4). Abdominal and perineal examination may reveal
evidence of trauma or malignancy.
Laboratory testing
Laboratory testing should include a complete blood count,
white blood count with blood cell differential, platelet
count, and coagulation profile to assess anaemia and detect
haematologic abnormalities [8,37]. Blood gas analysis is
essential to differentiate arterial and ischaemic priapism
(Table 5). Further laboratory testing should be directed by
history, clinical, and laboratory findings.
5.4.
Penile imaging
Colour duplex ultrasonography of the penis and perineum
is recommended in the evaluation of arterial priapism
because it can identify approximately 70% of cases and can
Table 4 – Key findings in priapism*
Corpora cavernosa fully rigid
Penile pain
Abnormal penile blood gas
Haematologic abnormalities
Recent intracorporeal injection
Perineal trauma
*
Adapted from Broderick et al. [8].
pCO2 (mm Hg)
pH
>90
< 40
7.40
40
50
7.35
<30
>60
<7.25
Adapted from Broderick et al. [8].
1a
LE = level of evidence.
5.3.
pO2 (mmHg)
Ischaemic
priapism
Arterial
priapism
Usually
Usually
Usually
Usually
Sometimes
Seldom
Seldom
Seldom
Seldom
Seldom
Sometimes
Usually
differentiate arterial from ischaemic priapism as an alternative or adjunct to blood gas analysis [21,38,39] (LE: 2b).
A pudendal arteriogram in selected patients can reveal a
characteristic blush at the site of the injury to the cavernosal
artery in patients with arterial priapism [40,41]. However,
due to its invasiveness and the lack of availability of colour
Duplex ultrasonography, it should be reserved for the
management of arterial priapism when embolisation is
undertaken [8,37] (LE: 3). Table 6 summarises the
recommendations on the diagnosis of priapism.
6.
Management of priapism
6.1.
Management of ischaemic priapism
Acute ischaemic priapism is an emergency condition, and
rapid intervention is compulsory in a stepwise approach
(LE: 4). The aim of any treatment is to restore penile
flaccidity, without pain, to prevent eventual chronic
damage to the corpora cavernosa. In many cases, penile
oedema may persist, with ecchymosis and partial erection
that could eventually mimic unresolved priapism.
6.1.1.
First-line treatments
First-line treatments in ischaemic priapism lasting >4 h are
highly recommended before any surgical treatment (LE: 4).
Table 6 – Recommendations on the diagnosis of priapism
Recommendation
A comprehensive history is the mainstay in priapism diagnosis
and can help to determine the underlying type of priapism.
Physical examination of the genitalia, the perineum, and the
abdomen must be included in the diagnostic evaluation of
priapism. It may help to determine the underlying type of
priapism.
Laboratory testing should include complete blood count, white
blood count with blood cell differential, platelet count, and
coagulation profile. Further laboratory testing should be
directed by the history and clinical and laboratory findings.
Colour duplex ultrasonography of the penis and perineum is
recommended for the differentiation between ischaemic and
arterial priapism and for localisation of the site of fistula in
arterial priapism.
Magnetic resonance imaging of the penis can predict smooth
muscle viability and erectile function restoration.
Selected pudendal arteriogram should be reserved for the
management of arterial priapism when embolisation
is undertaken.
GR = grade of recommendation.
GR
B
B
B
B
B
B
484
EUROPEAN UROLOGY 65 (2014) 480–489
Conversely, first-line treatments initiated beyond 72 h may
have benefits in relieving the unwanted erection and
associated pain, but they have little documented benefit
in terms of potency preservation (LE: 4).
Several first-line treatments have been described historically including exercise, ejaculation, ice packs, cold
baths, and cold water enemas [8]. However, there is a lack of
evidence on the efficacy of such measures. The so-called
simpler cases of drug-induced priapism are typically caused
by a single intracavernosal administration of a drug such as
alprostadil. The first step in treatment for this type of case
can be the direct injection of a sympathomimetic agent
(most often, phenylephrine or etilefrine), using a 30G
needle, without prior aspiration of blood from the corpora
cavernosa (LE: 4). However, these simpler cases can be
successfully treated with blood aspiration alone without
the need for a sympathomimetic agent (LE: 4).
Decompression of the corpora cavernosa usually promotes the recovery of intracorporal blood circulation, which
should result in the relief of penile pain and counteract local
acidotic and anoxic metabolic derangements caused by the
priapism itself. Blood aspiration may be performed with
intracorporeal access through the glans or with a percutaneous needle access on either lateral aspect of the proximal
penile shaft under local anaesthesia [42] (LE: 4). Overall,
aspiration must be continued until fresh red oxygenated
blood is aspired (LE: 4).
Options for intracavernosal sympathomimetic agents
include phenylephrine, etilefrine, ephedrine, epinephrine,
norepinephrine, and metaraminol [8,43–49] (LE: 2b). Phenylephrine has been suggested as the drug of choice due to its
high selectivity for the a1-adrenergic receptor, without
concomitant b-mediated ionotropic and chronotropic cardiac effects (LE: 4) [44,45]. Phenylephrine is usually diluted in
normal saline with a concentration of 100–500 mg/ml and
given in 1-ml doses every 3–5 min directly into the corpus
cavernosum, up to a maximum dosage of 1 mg for no more
than 1 h (LE: 4). A lower concentration or volume is
applicable for children and patients with severe cardiovascular disease and the potential for systemic cardiovascular
side effects [8,43–46] (LE: 4). Vital signs (blood pressure and
pulse) should be monitored every 15 min [47]. Potential
treatment-related side effects of intracavernous phenylephrine (and other sympathomimetic agents) include headache,
dizziness, hypertension, reflex bradycardia, tachycardia and
palpitations, and irregular cardiac rhythms.
Patients with ischaemic priapism may not respond
properly to conventional doses of phenylephrine due to
the attenuated contractile response associated with hypoxia and acidosis [50]. Higher doses, up to a total cumulative
dose of 50 000 mg, have been suggested to be of clinical
benefit (LE: 3) [44,45].
The management of sickle cell disease–related priapism
is similar to the approach previously described in other
cases of ischaemic priapism [9,51] (LE: 4). However, other
therapeutic practices may also need to be implemented
[51]. Specific measures for sickle cell disease–related
priapism include the administration of intravenous hydration and parental narcotic analgesia while preparing the
patient for aspiration and irrigation. In addition, supplemental oxygen administration is required and alkalinisation
with bicarbonate [9,18]. Exchange blood transfusion has
been also proposed, with the aim of increasing the tissue
delivery of oxygen.
6.1.2.
Second-line treatments
Second-line intervention typically refers to surgical intervention in the form of penile shunt surgery. In an acute
situation, surgery for ischaemic priapism should be
considered only when conservative management options
fail, with the specific purpose of relieving penile ischaemia
and the avoidance of corporal fibrosis (LE: 4) [8,43,52]. In
2009, the International Society for Sexual Medicine
Standards Committee stated that shunting should be
considered for priapism events lasting 72 h (LE: 4) [8].
In general, the type of shunt procedure chosen is
suggested by the surgeon’s preference and familiarity with
different techniques (LE: 4). However, it is preferable for
distal shunt procedures to be tried first (LE: 4). Proximal
shunting may be considered if distal procedures have failed
to relieve the priapism (LE: 4). However, the efficacy of this
treatment strategy is questionable, and cavernous biopsy
may be considered to diagnose muscle necrosis.
Data are not unique regarding the postoperative recovery rates of erectile function in men submitted to shunt
surgery for prolonged erections [53]. In this context,
priapism events prolonged >36 h appear to impair irreversibly erectile tissue both structurally and functionally
[54]. Overall, it has been considered that in patients
experiencing major ischaemic priapism lasting continuously for a prolonged duration (36 h), any shunt procedure
may only serve to limit pain sensations without adequately
preserving erectile functioning (LE: 4).
Four categories of shunt procedures have been reported
[1,8,52]: These include the percutaneous distal (corporoglanular) shunts (by Winter, Ebbehoj, Lue), the open distal
(corporoglanular) shunts (by Al-Ghorab, Burnett), the open
proximal (corporospongiosal) shunts (by Quackles, Sacher),
and the vein anastomoses/shunts (by Grayhack, Barry). It is
not possible to say that one procedure is more effective
than another due to the limited available data, particularly
the lack of data allowing accurate predictions of outcome
(LE: 4).
Intractable therapy-resistant acute ischaemic priapism
or episodes lasting >48–72 h usually result in complete
erectile function impairment, along with possible major
penile deformity. In these cases, immediate penile prosthesis surgery has been recommended because it seems to
avoid the difficulty of surgery and the risk of complications
(eg, urethral injury, tunical erosions, infection, and/or
penile shortening) that may occur whenever surgery is
performed some time later after long-term corporal fibrosis
has already developed [55–58] (LE: 3). Potential complications that could compromise immediate penile prosthesis
implantation include distal erosion and cavernositis [56,58],
along with a mild rate of revision surgery [56]. Table 7
summarises the recommendations on the treatment of
ischaemic priapism.
EUROPEAN UROLOGY 65 (2014) 480–489
485
Table 7 – Recommendations on the treatment of ischaemic priapism
Recommendation
GR
Ischaemic priapism is an emergency condition; rapid intervention is compulsory.
The specific aim of any emergent treatment is to retrieve penile flaccidity, without pain to prevent eventual chronic damage to the corpora
cavernosa.
Management of ischaemic priapism should start as early as possible (within 4–6 h) and should follow a stepwise approach. Erectile function
preservation is directly related to the duration of priapism.
The first step in the management of ischaemic priapism is decompression of the corpora cavernosa by penile aspiration until fresh red blood is
obtained. In cases of drug-induced priapism after intracavernous injections of vasoactive agents for the treatment of erectile dysfunction, blood
aspiration can be replaced by intracavernous injection of a sympathomimetic drug as the first step.
In the case of priapism recurrence after aspiration, the next step is intracavernous injection of a sympathomimetic drug. Phenylephrine is the
recommended drug due to its favourable safety profile on the cardiovascular system compared with other drugs. Phenylephrine is usually diluted
in normal saline with a concentration of 100–500 mg/ml and given in 1-ml doses every 3–5 min directly into the corpus cavernosum, up to a
maximum dosage of 1 mg for no more than 1 h. Patients at high cardiovascular risk should be given lower doses. Patient monitoring is highly
recommended.
In case of priapism recurrence after aspiration and intracavernous injection of a sympathomimetic drug, these steps should be repeated several
times before considering surgical intervention. No clear recommendation for the highest phenylephrine dose can be given.
Ischaemic priapism due to sickle cell anaemia is treated in the same fashion as idiopathic ischaemic priapism. Other supportive measures are
recommended (intravenous hydration, oxygen administration with alkalisation with bicarbonates, blood exchange transfusions), but these
should not delay initial treatment.
Surgical treatment is recommended only when blood aspiration and intracavernous injection of sympathomimetic drugs have failed or for
priapism events lasting 72 h.
Distal shunt surgical procedures should be performed first followed by proximal procedures in case of failure. The efficacy of this treatment
strategy is questionable, and cavernous biopsy may be considered to diagnose muscle necrosis. No clear recommendation of one type of shunt
over another can be given.
In cases of priapism presenting >36 h after onset, or in cases for which all interventions have failed, erectile dysfunction is inevitable and the
immediate implantation of a penile prosthesis is recommended. Implantation of penile prosthesis at a later stage can be difficult due to severe
corporal fibrosis.
B
C
B
C
B
C
B
C
C
B
GR = grade of recommendation.
6.2.
Management of arterial priapism
The management of high-flow priapism is not an emergency because the penis is not ischaemic. Definitive management can therefore be considered and should be discussed
with the patient so he understands the risks and complications of treatment (LE: 3) [8,37].
Conservative management, which may include the use of
ice applied to the perineum or site-specific perineal
compression, has been reported to be successful [21,22,59].
It is an option in all cases, particularly children [60] (LE: 3).
The fistula occasionally closes spontaneously. Even in those
cases when it does not, the response to a sexual stimulus does
allow for intercourse. Blood aspiration is not an option for the
treatment of arterial priapism, and the use of a-adrenergic
antagonists is not recommended due to potential severe
adverse effects (eg, transfer of the drug into the systemic
circulation).
Selective arterial embolisation can be performed using
an autologous clot [61], gel foam, or sponge, or more
permanent substances such as coils [62] or acrylic glue [63],
with success rates up to 89% (LE:3). The series reporting the
efficacy of these different approaches are all uncontrolled
and relatively small, so although the relative merits of the
different substances can be debated, there are no robust
data to demonstrate superiority.
The use of an autologous clot has some attractions, at
least theoretically. It temporarily seals the fistula, but when
the clot is lysed, the arterial damage has usually resolved
and the blood flow of the penis can therefore return to
normal. The use of a permanent device, such as a coil, would
permanently block an artery and may lead to adverse effects
upon spontaneous sexual function. Following percutaneous
embolisation, a follow-up is appropriate within 1–2 wk.
Assessment by clinic examination and by colour Duplex
ultrasonography may be helpful in determining whether
the embolisation has been successful [39]. Recurrence rates
of 7–27% after a single treatment of embolisation have been
reported [64] (LE: 3). In a few cases, repeat embolisation is
necessary. Sexual function following embolisation can be
adversely affected, although there is a full restoration of
potency in approximately 80% of men [64] (LE: 3).
Embolisation in children, although reportedly successful,
is technically challenging and requires treatment within a
specialist paediatric vascular radiology department [65].
Surgical treatment consists of selective ligation of the
fistula through a transcorporeal approach under the
guidance of colour Duplex ultrasound [1,66]. However, it
is technically challenging and may pose significant risks,
mainly erectile dysfunction due to accidental ligation of the
cavernous artery instead of the fistula. Today, it is rarely
performed and only in cases with pseudocapsular formation
around the fistula (because this makes it easier to identify
the fistula), contraindications for selective embolisation, no
availability of the technique, or embolisation failure (LE: 4).
Table 8 summarises the recommendations on the treatment
of arterial priapism.
6.3.
Management of stuttering priapism
The primary goal in the management of patients with
stuttering priapism is the prevention of future episodes.
This goal can usually be achieved pharmacologically. The
management of each acute episode is similar to that for
486
EUROPEAN UROLOGY 65 (2014) 480–489
Table 8 – Recommendations on the treatment of arterial priapism
Recommendation
The management of high-flow priapism is not an emergency, and
definitive management can therefore be considered.
Conservative management includes the use of ice applied to the
perineum or site-specific perineal compression. It may be
successful particularly in children.
Selective artery embolisation, using temporary or permanent
substances, is the suggested treatment modality and has high
success rates.
The recurrence of arterial priapism following selective artery
embolisation requires the procedure to be repeated.
The preservation rate of sexual function preservation rates is
about 80%. No definitive statement can be made on the best
substance for embolisation in terms of sexual function
preservation.
Selective surgical ligation of the fistula should be reserved as a last
treatment option when embolisation has failed.
GR
B
C
B
B
C
C
GR = grade of recommendation.
ischaemic priapism, namely aspiration/irrigation in combination with intracavernous injections of a-adrenergic
agonists. Unfortunately, the efficacy and safety of the
various treatment modalities reported in the medical
literature have been poorly characterised [9,18,67].
The aim of hormonal manipulation is to smother
circulating testosterone levels to suppress the action of
androgens on penile erection [9,18,68]. This can be done
through the use of gonadotropin-releasing hormone agonists or antagonists [69] (LE: 4). Potential side effects may
include hot flushes, gynaecomastia, impaired erectile
function, loss of libido, and asthenia. Antiandrogens
(ie, flutamide, bicalutamide) [70] and oestrogens [71]
may also be efficacious (LE: 4). The 5a-reductase inhibitors
(finasteride, dutasteride) block the conversion of testosterone to dihydrotestosterone. In a noncontrolled study of
35 patients with sickle cell disease, finasteride, 3 or 5 mg
daily for 120 d, produced a significant decrease in the number
of recurrent priapic episodes [72] (LE: 3). Finally, ketoconazole, an antifungal agent that reduces adrenal and testicular
androgen production, may also be a potential treatment for
priapism [73] (LE: 4).
The duration of hormonal treatment for effective
suppression of recurrent priapic events varies from weeks
to years and depends on the type of agent and the
investigator suggestions. Because this information has been
derived from small case series in men with idiopathic
stuttering priapism and patients with sickle cell disease, it is
not possible to reach any clear conclusions. Hormonal
agents have a contraceptive effect and interfere with
normal sexual maturation. Caution is therefore strongly
advised when prescribing hormonal treatments to prepubertal boys, adolescents, or those men who are trying to
impregnate their female partner.
Studies of oral a-adrenergic agonists including pseudoephedrine and etilefrine (50–100 mg daily) have suggested
that limited daily dosing with these agents is effective in up
to 72% [74,75]. Drug therapy is generally prescribed at
bedtime. Side effects have included tachycardia and
palpitations.
Digoxin regulates smooth muscle tone through a number
of different pathways leading to penile detumescence
[9,18]. A small clinical double-blind placebo-controlled
study using digoxin (0.25–0.5 mg daily) produced a
decrease in sexual desire and excitement with a concomitant reduction in penile rigidity [76] (LE: 2b). Common side
effects may include a decreased libido, anorexia, nausea,
vomiting, confusion, blurred vision, headache, gynaecomastia, rash, and arrhythmia.
Terbutaline is a b-agonist that causes vasodilation,
resulting in smooth muscle relaxation of the vasculature
[18]. Oral terbutaline was suggested as a compound to
prevent stuttering priapism with detumescence rates of
36% in patients with alprostadil-induced priapism [77]
(LE: 3). In the only randomised placebo-controlled study in
patients with pharmacologically induced priapism, detumescence occurred in 42% of the terbutaline-treated group
compared with only 15% in the placebo-treated group [78]
(LE: 1b). Side effects may include nervousness, shakiness,
drowsiness, heart palpitations, headache, dizziness, hot
flashes, nausea, and weakness.
Gabapentin is a drug with anticonvulsant, antinociceptive, and anxiolytic properties. Its proposed mechanism of
action is the inhibition of voltage-gated calcium channels,
which in turn attenuates synaptic transmission. It is given at
the dose of 400 mg four times a day up to 2400 mg daily,
until a complete penile detumescence occurs, with subsequent maintenance administration of gabapentin 300 mg
daily [79] (LE: 4). Side effects may include anorgasmia and
impaired erectile function.
Baclofen is a g-aminobutyric acid (GABA) derivative that
can inhibit penile erection and ejaculation through GABA
activity and is used to prevent recurrent reflexogenic
erections or prolonged erections from neurologic diseases
[18]. Intrathecal baclofen dosing is more effective than oral
administration [9,80,81] (LE: 4). Side effects may include
drowsiness, confusion, dizziness, weakness, fatigue, headache, hypotension, and nausea.
Hydroxyurea is an established treatment for ameliorating sickle cell disease in most patients and in improving
their life expectancy [51]. For patients with sickle cell
disease and recurrent priapism, there is limited evidence to
suggest a medical prophylactic role for hydroxyurea (LE: 3)
[82]. Potential side effects may be oligospermia and leg
ulcers.
PDE5-Is act by increasing PDE5 function (ie, by increasing the concentration of cGMP in the smooth muscle in a
nitric oxide dysfunctional state). This state occurs in
priapism in association with the underlying disease state.
It may result in a change in the nitric oxide pathway,
producing downregulation of PDE5 in the penis and
therefore preventing the complete degradation of cGMP
in the corpora cavernosa [9,18]. Low doses of PDE5-I
(sildenafil 25 mg daily or tadalafil 5 mg three times weekly)
have a paradoxical effect in alleviating and preventing
stuttering priapism, mainly in patients with idiopathic and
sickle cell disease–associated priapism [9,18,83,84] (LE: 3).
Treatment should be started only when the penis is in its
flaccid state, and there may be a delay of 1 wk before
EUROPEAN UROLOGY 65 (2014) 480–489
487
Table 9 – Recommendations on the treatment of stuttering priapism
Recommendation
GR
The primary goal in the management of patients with stuttering priapism is the prevention of future episodes, which can generally be
achieved pharmacologically. The management of each acute episode is similar to that for ischaemic priapism.
Hormonal therapies (mainly gonadotropin-receptor hormone agonists or antagonists) and/or antiandrogens may be used for the
prevention of future episodes. They should not be used before sexual maturation is reached.
Phosphodiesterase type 5 inhibitors have a paradoxical effect in alleviating and preventing stuttering priapism, mainly in patients with
idiopathic and sickle cell disease–associated priapism. Treatment should be initiated only when the penis is in its flaccid state.
Other systemic drugs (digoxin, a-adrenergic agonists, baclofen, gabapentin, terbutaline) can be considered, but data are even more limited.
Intracavernosal self-injections at home of sympathomimetic drugs can be considered for the treatment of acute episodes on an interim
basis until ischaemic priapism has been alleviated.
B
C
C
C
C
GR = grade of recommendation.
treatment is effective. There are no reported impairments in
male sexual function (LE: 3). Table 9 summarises the
recommendations on the treatment of stuttering priapism.
Author contributions: Konstantinos Hatzimouratidis had full access to all
the data in the study and takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Study concept and design: Salonia, Hatzimouratidis, Wespes.
Acquisition of data: Salonia, Hatzimouratidis.
Analysis and interpretation of data: Salonia, Hatzimouratidis.
Drafting of the manuscript: Salonia, Hatzimouratidis
Critical revision of the manuscript for important intellectual content:
Salonia, Hatzimouratidis, Wespes, Eardley, Giuliano, Hatzichristou,
Moncada, Vardi.
Statistical analysis: Salonia, Hatzimouratidis.
Obtaining funding: None.
References
[1] Montague DK, Jarow J, Broderick GA, et al. American Urological
Association guideline on the management of priapism. J Urol 2003;
170:1318–24.
[2] Kulmala RV, Lehtonen TA, Tammela TL. Priapism, its incidence and
seasonal distribution in Finland. Scand J Urol Nephrol 1995;29:
93–6.
[3] Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of
priapism in the general population. Urology 2001;57:970–2.
[4] Furtado PS, Costa MP, Ribeiro do Prado Valladares F, et al. The
prevalence of priapism in children and adolescents with sickle cell
disease in Brazil. Int J Hematol 2012;95:648–51.
[5] Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell
disease complications: a clinical study of 179 cases. Haematologica
2012;97:1136–41.
[6] Olujohungbe AB, Adeyoju A, Yardumian A, et al. A prospective diary
Administrative, technical, or material support: Salonia, Hatzimouratidis.
study of stuttering priapism in adolescents and young men with
Supervision: Salonia, Hatzimouratidis, Wespes.
sickle cell anemia: report of an international randomized control
Other (specify): None.
trial—the priapism in sickle cell study. J Androl 2011;32:375–82.
[7] Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell
Financial disclosures: Konstantinos Hatzimouratidis certifies that all
conflicts of interest, including specific financial interests and relation-
disease; incidence, risk factors and complications—an international
multicentre study. BJU Int 2002;90:898–902.
ships and affiliations relevant to the subject matter or materials
[8] Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A,
discussed in the manuscript (eg, employment/affiliation, grants or
Shamloul R. Priapism: pathogenesis, epidemiology, and manage-
funding, consultancies, honoraria, stock ownership or options, expert
ment. J Sex Med 2010;7:476–500.
testimony, royalties, or patents filed, received, or pending), are the
[9] Levey HR, Kutlu O, Bivalacqua TJ. Medical management of ischemic
following: Andrea Salonia is a company consultant for Bayer Schering
stuttering priapism: a contemporary review of the literature. Asian
Pharma, Eli Lilly Italy, and Pierre Fabre. Ian Eardley is a company
J Androl 2012;14:156–63.
consultant for Lilly, Allergan, and Bayer; receives company speaker
[10] Berger R, Billups K, Brock G, et al. Report of the American Foundation
honoraria from Lilly, Allergan, Bayer, and Menarini; and receives
for Urologic Disease (AFUD) Thought Leader Panel for evaluation
fellowships and travel grants from Lilly. François Giuliano is a company
consultant for Pfizer, Johnson & Johnson, Bayer, Lilly, Pfizer, and
Allergen; receives company speaker honoraria from Lilly, Pfizer, Johnson
and treatment of priapism. Int J Impot Res 2001(Suppl 5):S39–43.
[11] El-Bahnasawy MS, Dawood A, Farouk A. Low-flow priapism: risk
factors for erectile dysfunction. BJU Int 2002;89:285–90.
& Johnson, and Sanofi-Aventis; participates in trials for Eli Lilly and
[12] Spycher MA, Hauri D. The ultrastructure of the erectile tissue in
Pfizer; and receives research grants from Bayer-Schering, AeternaZentaris, Sanofi-Aventis, Spectrum, DSP, Johnson & Johnson, and GSK. He
priapism. J Urol 1986;135:142–7.
[13] Pohl J, Pott B, Kleinhans G. Priapism: a three-phase concept of
is a company consultant for Menarini. Dimitrios Hatzichristou receives
management according to aetiology and prognosis. Br J Urol 1986;58:
company speaker honoraria from Menarini, Bayer, and Lilly. He
113–8.
[14] Junemann KP, Persson-Junemann C, Alken P. Pathophysiology of
participates in trials for GSK, Astellas, Lilly, Ferring, and Pfizer. He is
an advisory board member for Lilly and Menarini. Ignacio Moncada is a
company consultant for Lilly, Bayer, and Andromedical. He receives
company speaker honoraria from Lilly, Bayer, GSK, AMS, and Medispect;
erectile dysfunction. Semin Urol 1990;8:80–93.
[15] Porst H. The rationale for prostaglandin E1 in erectile failure: a
survey of worldwide experience. J Urol 1996;155:802–15.
participates in trials for Lilly, Bayer, and Auxilium; and is a company
[16] Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of
consultant for Menarini. Yoram Vardi has equity interests in Pfizer, Lilly,
outcomes of an intracavernosal injection therapy programme. BJU
and Bayer. He participates in trials for J&J and is a company consultant
Int 2012;110:1787–91.
for Medispec. Eric Wespes is a company consultant for Pfizer, Bayer, and
[17] Nelson III JH, Winter CC. Priapism: evolution of management in
Lilly. Konstantinos Hatzimouratidis receives company speaker honoraria
48 patients in a 22-year series. J Urol 1977;117:455–8.
[18] Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the
from Lilly and Jannsen-Cilag. He participates in trials for Lilly.
pathophysiology of sickle cell disease-associated priapism. J Sex
Funding/Support and role of the sponsor: None.
Med 2012;9:79–87.
488
EUROPEAN UROLOGY 65 (2014) 480–489
[19] Lagoda G, Sezen SF, Cabrini MR, Musicki B, Burnett AL. Molecular
[40] Kolbenstvedt A, Egge T, Schultz A. Arterial high flow priapism role
analysis of erection regulatory factors in sickle cell disease associ-
of radiology in diagnosis and treatment. Scand J Urol Nephrol Suppl
ated priapism in the human penis. J Urol 2013;189:762–8.
1996;179:143–6.
[20] Lin YH, Kim JJ, Stein NB, Khera M. Malignant priapism secondary to
[41] Kang BC, Lee DY, Byun JY, Baek SY, Lee SW, Kim KW. Post-traumatic
metastatic prostate cancer: a case report and review of literature.
arterial priapism: colour Doppler examination and superselective
Rev Urol 2011;13:90–4.
arterial embolization. Clin Radiol 1998;53:830–4.
[21] Hakim LS, Kulaksizoglu H, Mulligan R, Greenfield A, Goldstein I.
[42] Ateyah A, Rahman El-Nashar A, Zohdy W, Arafa M, Saad El-Den H.
Evolving concepts in the diagnosis and treatment of arterial high
Intracavernosal irrigation by cold saline as a simple method of
flow priapism. J Urol 1996;155:541–8.
[22] Hatzichristou D, Salpiggidis G, Hatzimouratidis K, et al. Management strategy for arterial priapism: therapeutic dilemmas. J Urol
2002;168:2074–7.
[23] Kuefer R, Bartsch Jr G, Herkommer K, Kramer SC, Kleinschmidt K,
Volkmer BG. Changing diagnostic and therapeutic concepts in highflow priapism. Int J Impot Res 2005;17:109–13.
[24] Witt MA, Goldstein I, Saenz de Tejada I, Greenfield A, Krane RJ.
Traumatic laceration of intracavernosal arteries: the pathophysiology of nonischemic, high flow, arterial priapism. J Urol 1990;143:
129–32.
[25] Steers WD, Selby Jr JB. Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to
medical and surgical treatments. J Urol 1991;146:1361–3.
[26] Ricciardi Jr R, Bhatt GM, Cynamon J, Bakal CW, Melman A. Delayed
high flow priapism: pathophysiology and management. J Urol 1993;
149:119–21.
[27] Dubocq FM, Tefilli MV, Grignon DJ, Pontes JE, Dhabuwala CB. High
flow malignant priapism with isolated metastasis to the corpora
cavernosa. Urology 1998;51:324–6.
[28] Todd NV. Priapism in acute spinal cord injury. Spinal Cord 2011;49:
1033–5.
treating iatrogenic prolonged erection. J Sex Med 2005;2:248–53.
[43] Burnett AL, Sharlip ID. Standard operating procedures for priapism.
J Sex Med 2013;10:180–94.
[44] Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N.
Management of ischemic priapism with high-dose intracavernosal
phenylephrine: from bench to bedside. J Sex Med 2006;3:918–22.
[45] Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating
the effects of high-dose phenylephrine in the management of
prolonged ischaemic priapism. J Sex Med 2008;5:2152–9.
[46] Davila HH, Parker J, Webster JC, Lockhart JL, Carrion RE. Subarachnoid hemorrhage as complication of phenylephrine injection for
the treatment of ischemic priapism in a sickle cell disease patient.
J Sex Med 2008;5:1025–8.
[47] Muruve N, Hosking DH. Intracorporeal phenylephrine in the treatment of priapism. J Urol 1996;155:141–3.
[48] Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR.
Outpatient penile aspiration and epinephrine irrigation for young
patients with sickle cell anemia and prolonged priapism. Blood
2000;95:78–82.
[49] Roberts JR, Price C, Mazzeo T. Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department. J Emerg Med 2009;36:285–9.
[29] Lutz A, Lacour S, Hellstrom W. Conversion of low-flow to high-flow
[50] Moon DG, Lee DS, Kim JJ. Altered contractile response of penis
priapism: a case report and review (CME). J Sex Med 2012;9:951–4,
under hypoxia with metabolic acidosis. Int J Impot Res 1999;11:
quiz 955.
[30] McMahon CG. High flow priapism due to an arterial-lacunar fistula
complicating initial veno-occlusive priapism. Int J Impot Res 2002;
14:195–6.
[31] Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of
265–71.
[51] Bartolucci P, Galacteros F. Clinical management of adult sickle-cell
disease. Curr Opin Hematol 2012;19:149–55.
[52] Burnett AL. Surgical management of ischemic priapism. J Sex Med
2012;9:114–20.
priapism in sickle cell disease with oral and self-administered
[53] Nixon RG, O’Connor JL, Milam DF. Efficacy of shunt surgery for
intracavernous injection of etilefrine. Urology 1996;47:777–81,
refractory low flow priapism: a report on the incidence of failed
discussion 781.
detumescence and erectile dysfunction. J Urol 2003;170:883–6.
[32] Fowler Jr JE, Koshy M, Strub M, Chinn SK. Priapism associated with
[54] Bennett N, Mulhall J. Sickle cell disease status and outcomes of
the sickle cell hemoglobinopathies: prevalence, natural history and
African-American men presenting with priapism. J Sex Med 2008;
sequelae. J Urol 1991;145:65–8.
5:1244–50.
[33] Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR.
[55] Upadhyay J, Shekarriz B, Dhabuwala CB. Penile implant for intrac-
Prevalence of priapism in children and adolescents with sickle cell
table priapism associated with sickle cell disease. Urology 1998;51:
anemia. J Pediatr Hematol Oncol 1999;21:518–22.
638–9.
[34] Broderick GA, Harkaway R. Pharmacologic erection: time-dependent
[56] Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a
changes in the corporal environment. Int J Impot Res 1994;6:
penile prosthesis for acute ischaemic priapism. Eur Urol 2009;56:
9–16.
1033–8.
[35] Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL.
[57] Salem EA, El Aasser O. Management of ischemic priapism by penile
Phosphodiesterase-5A dysregulation in penile erectile tissue is a
prosthesis insertion: prevention of distal erosion. J Urol 2010;183:
mechanism of priapism. Proc Natl Acad Sci USA 2005;102:1661–6.
2300–3.
[36] Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P.
[58] Sedigh O, Rolle L, Negro CL, et al. Early insertion of inflatable
RhoA expression is controlled by nitric oxide through cGMP-
prosthesis for intractable ischemic priapism: our experience and
dependent protein kinase activation. J Biol Chem 2003;278:
9472–80.
[37] Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and
surgical management. Urol Clin North Am 2011;38:185–94.
review of the literature. Int J Impot Res 2011;23:158–64.
[59] Arango O, Castro R, Dominguez J, Gelabert A. Complete resolution of
post-traumatic high-flow priapism with conservative treatment.
Int J Impot Res 1999;11:115–7.
[38] Bertolotto M, Quaia E, Mucelli FP, Ciampalini S, Forgacs B, Gattuccio I.
[60] Corbetta JP, Duran V, Burek C, et al. High flow priapism: diagnosis
Color Doppler imaging of posttraumatic priapism before and after
and treatment in pediatric population. Pediatr Surg Int 2011;27:
selective embolization. Radiographics 2003;23:495–503.
1217–21.
[39] Bertolotto M, Zappetti R, Pizzolato R, Liguori G. Color Doppler
[61] Numan F, Cantasdemir M, Ozbayrak M, et al. Posttraumatic non-
appearance of penile cavernosal-spongiosal communications in
ischemic priapism treated with autologous blood clot embolization.
patients with high-flow priapism. Acta Radiol 2008;49:710–4.
J Sex Med 2008;5:173–9.
EUROPEAN UROLOGY 65 (2014) 480–489
489
[62] Liu BX, Xin ZC, Zou YH, et al. High-flow priapism: superselective
[74] Mocniak M, Durkin CM, Early K. The use of Sudafed for priapism in
cavernous artery embolization with microcoils. Urology 2008;72:
pediatric patients with sickle cell disease. J Pediatr Nurs 2012;27:
571–3, discussion 573–4.
82–4.
[63] Numan F, Cakirer S, Islak C, et al. Posttraumatic high-flow priapism
[75] Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the
treated by N-butyl-cyanoacrylate embolization. Cardiovasc Inter-
prevention of priapism in adult sickle cell disease. Br J Haematol
vent Radiol 1996;19:278–80.
2002;118:918–21.
[64] Savoca G, Pietropaolo F, Scieri F, Bertolotto M, Mucelli FP, Belgrano
[76] Gupta S, Salimpour P, Saenz de Tejada I, et al. A possible mechanism
E. Sexual function after highly selective embolization of cavernous
for alteration of human erectile function by digoxin: inhibition of
artery in patients with high flow priapism: long-term followup.
corpus cavernosum sodium/potassium adenosine triphosphatase
J Urol 2004;172:644–7.
activity. J Urol 1998;159:1529–36.
[65] Cantasdemir M, Gulsen F, Solak S, Numan F. Posttraumatic high-
[77] Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline and
flow priapism in children treated with autologous blood clot em-
pseudoephedrine in management of prostaglandin E1-induced
bolization: long-term results and review of the literature. Pediatr
Radiol 2011;41:627–32.
[66] Shapiro RH, Berger RE. Post-traumatic priapism treated with selective cavernosal artery ligation. Urology 1997;49:638–43.
[67] Morrison BF, Burnett AL. Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep 2012;13:268–76.
[68] Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism
mechanism and rationale treatment for recurrent priapism. Asian
J Androl 2008;10:88–101.
[69] Levine LA, Guss SP. Gonadotropin-releasing hormone analogues
in the treatment of sickle cell anemia-associated priapism. J Urol
1993;150:475–7.
[70] Yamashita N, Hisasue S, Kato R, et al. Idiopathic stuttering priapism:
recovery of detumescence mechanism with temporal use of antiandrogen. Urology 2004;63:1182–4.
[71] Shamloul R, el Nashaar A. Idiopathic stuttering priapism treated
successfully with low-dose ethinyl estradiol: a single case report.
J Sex Med 2005;2:732–4.
[72] Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ.
Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology 2009;74:1054–7.
prolonged erections. Urology 1993;42:51–3, discussion 53–4.
[78] Priyadarshi S. Oral terbutaline in the management of pharmacologically induced prolonged erection. Int J Impot Res 2004;16:
424–6.
[79] Perimenis P, Athanasopoulos A, Papathanasopoulos P, Barbalias G.
Gabapentin in the management of the recurrent, refractory, idiopathic priapism. Int J Impot Res 2004;16:84–5.
[80] Vaidyanathan S, Watt JW, Singh G, et al. Management of recurrent
priapism in a cervical spinal cord injury patient with oral baclofen
therapy. Spinal Cord 2004;42:134–5.
[81] D’Aleo G, Rifici C, Kofler M, Saltuari L, Bramanti P. Favorable response
to intrathecal, but not oral, baclofen of priapism in a patient with
spinal cord injury. Spine (Phila Pa 1976) 2009;34:E127–9.
[82] Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease
patients with priapism treated by hydroxyurea. Am J Hematol 2004;
77:45–9.
[83] Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL,
Champion HC. Establishment of a transgenic sickle-cell mouse
model to study the pathophysiology of priapism. J Sex Med 2009;
6:2494–504.
[84] Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of
[73] DeCastro BJ, Costabile RA, McMann LP, Peterson AC. Oral ketocona-
the use of phosphodiesterase type 5 inhibitors in a pharmacologic
zole for prevention of postoperative penile erection: a placebo con-
prevention program for recurrent priapism. J Sex Med 2006;3:
trolled, randomized, double-blind trial. J Urol 2008;179:1930–2.
1077–84.